



**Overview**

- Profound Medical is a Canadian medical device company that has commercialized a unique and minimally invasive technique to ablate the prostate gland.
- Our novel technology combines real-time MR imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise procedure tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery.
- Current therapies (radiation, surgery) may bring undesirable complications: incontinence, impotency and bowel problems. Profound's technology has the potential for fewer adverse side effects.
- Technology developed at Sunnybrook Research Institute.
- Management team has extensive experience commercializing medical devices, specifically ablation technologies.
- Partnership with Philips announced in July 2015.
- Strategic Agreement with Siemens announced Feb. 2016, Sales and Marketing Agreement announced May, 2016

Heating Pattern



The Procedure



**Prostate Cancer Treatment Options**

Robotic Prostatectomy	IMRT (Intensity Modulated Radiation Therapy)	HIFU (High-Intensity Focused Ultrasound)	TULSA-PRO™
<ul style="list-style-type: none"> <li>+ Certainty of removing whole gland</li> <li>+ Good outcome data</li> <li>- Invasive</li> <li>- Hospital stay</li> <li>- Post-surgical complications</li> <li>- High cost</li> </ul>	<ul style="list-style-type: none"> <li>+ Non-invasive</li> <li>- Collateral tissue damage</li> <li>- Multiple visits required</li> <li>- Recurrence</li> <li>- High cost</li> </ul>	<ul style="list-style-type: none"> <li>+ Minimally invasive</li> <li>- Transrectal delivery can result in complications</li> <li>- Collateral tissue damage</li> <li>- Prostate volume must be &lt; 40 cc</li> <li>- Significant capital equipment cost</li> </ul>	<ul style="list-style-type: none"> <li>+ Minimally invasive</li> <li>+ Quick treatment time</li> <li>+ Highly accurate</li> <li>+ Real-time MRI- guided</li> <li>+ Prostate volume &lt; 90 cc</li> <li>+ Low complication rates</li> <li>- Requires compatible MRI equipment</li> </ul>

**Development & Commercialization**

- The Phase 1 trial has demonstrated that MRI-guided TULSA provides accurate treatment planning, real-time thermal dosimetry and precise control of prostate ablation to within 1.3 mm, with a well-tolerated side-effect profile.
- Read the results: European Urology Publication, Abstract, [Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase I Clinical Trial](#), Prof. Joseph L. Chin., M.D.
- Profound will launch a 110 patient, multi-jurisdictional Pivotal Trial in Q2 2016.
- Patents: 5 issued in U.S. (System and Method), 7 pending in U.S., 6 pending Foreign Applications.
- Technology compatible with Philips and Siemens MRI platforms.
- Potential other applications include: 1) Focal therapy: targeted ablation of cancerous tissue, leaving benign prostate tissue unharmed, and 2) The treatment of benign prostatic hyperplasia (BPH).

**Regulatory Status**

- TULSA-PRO™ has CE Marking. Regulatory Authorization is pending for all other jurisdictions.

**Selected Financial Data**

<b>Exchange &amp; Ticker</b> (commenced trading June 2015)	<b>TSXV: PRN</b>
<b>Cash</b> (@ March 31, 2016)	16.9MM
<b>Debt:</b>	FedDev \$0.8MM HTX \$1.3MM Knight \$4.0MM
<b>Common Shares</b> (@ March 31, 2016) Basic; Fully Diluted	39.5MM;43.8MM
<b>Significant Shareholders:</b>	BDC 24.8% Genesys 23.1% Knight 7.7%